Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)Piero Barbanti, Gabriella Egeo, Cinzia Aurilia et al.|The Journal of Headache and Pain|2022Cited by 105
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational studyPiero Barbanti, Cinzia Aurilia, Gabriella Egeo et al.|Journal of Neurology|2024Cited by 37
Fremanezumab in the Prevention of High-Frequency Episodic and Chronic Migraine: A 12-Week, Multicenter, Real-Life, Cohort Study (The FRIEND Study).Piero Barbanti, Fabrizio Vernieri, Gabriella Egeo et al.|Research Square|2021Cited by 6
Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)Piero Barbanti, Gabriella Egeo, Cinzia Aurilia et al.|The Journal of Headache and Pain|2022Cited by 5
Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE)Piero Barbanti, Giacomo Querzola, Giulia Fiorentini et al.|The Journal of Headache and Pain|2025Cited by 4